Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clin...

詳細記述

保存先:
書誌詳細
出版年:Haematologica
主要な著者: Dimopoulos, Meletios A., San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H. Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A. Kate, Khokhar, Nushmia Z., Avet-Loisea, Hervé, Usmani, Saad Z.
フォーマット: Artigo
言語:Inglês
出版事項: Ferrata Storti Foundation 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6269302/
https://ncbi.nlm.nih.gov/pubmed/30237262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.194282
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料